What Oshen does

Oshen is a private evergreen investment firm focused on the 'Better Ageing' sector, deploying capital into medtech and biotech companies that develop technologies to improve quality of life during the ageing process. The firm invests across the full spectrum from early-stage to market-ready companies, with a stated preference for IP-rich businesses whose technologies are patent-protected. Oshen partners globally with leading scientific institutions and companies to provide strategic benefit, value, and market access to its portfolio companies, and it works directly with founders and management teams on capital deployment, product development, and exit outcomes (M&A, IPOs, strategic collaborations).

The firm is led by Managing Partner Didier Cowling, a Cambridge-trained chemist and biochemist with 30+ years in life sciences, alongside partners Justin Cahill (Trinity College Dublin graduate with experience founding a Nasdaq-listed business in 2017) and Peter Wang (University of Toronto CS degree; Johns Hopkins MBA in Healthcare, Technology, and Innovation). The leadership team is distributed across Switzerland, Ireland, Luxembourg, and North America, with investment exposure spanning China, Ireland, Sweden, UK, Switzerland, and the Middle East. Oshen operates general offices in Switzerland and Luxembourg, and its primary public contact is [email protected].

Oshen generates returns through capital appreciation on its portfolio investments rather than through product sales or licensing royalties. It does not disclose fund size, AUM, revenue, or specific portfolio companies. There are no disclosed products, SaaS offerings, APIs, or proprietary technology platforms — Oshen's core offering is patient capital, strategic operating support, and access to a global scientific and commercial network.

Name

Oshen

Legal name

Oshen

Website

https://oshenbio.com

Company type

Private

Operating status

Operating

Short description

Oshen is a private evergreen investment firm that deploys patient capital into IP-rich medtech and biotech companies focused on improving quality of life during ageing, working directly with founders and management teams globally.

Ownership category

akta.pro rank

Product category

Life Sciences Investment

SIC

Investment Advice (6282)

akta.pro primary industry

Endowment / OCIO-Style Multi-Manager Platforms (FSANAGAG)

Keywords

• Life sciences investing
• Medtech venture capital
• Biotech investment firm
• Better ageing innovation
• Evergreen investment vehicle

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns: As an evergreen investment vehicle, Oshen generates returns through capital appreciation, mergers and acquisitions, IPOs, and strategic collaborations with healthcare companies within their portfolio of medtech and biotech investments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Oshen is an evergreen investment vehicle that deploys capital into medtech and biotech companies in the "Better Ageing" sector, from early-stage ventures to market-ready businesses with patent-protected technologies. Beyond providing funding, the firm partners with management teams to support product development from lab to market launch and assists with M&A, IPOs, and strategic healthcare collaborations. The firm pairs its investment capital with access to a global network of leading scientific institutions and companies to provide strategic benefit, value, and market access to portfolio companies.

Product overview

Oshen is an evergreen investment firm focused on the 'Better Ageing' sector, investing in biotech and medtech innovations that improve quality of life as people age. The company deploys capital across early-stage to market-ready companies with IP-rich, patent-protected technologies. As an investment vehicle rather than a product company, Oshen does not offer distinct product modules or SaaS offerings — its core offering is investment capital, strategic support, and access to global partnerships for its portfolio companies.

Differentiator

Problem solved

Functional benefit

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Leading Scientific Institutions and CompaniescoreStrategic or Co-development PartnerOshen partners globally with leading scientific institutions and companies working at the forefront of better ageing science. These partnerships offer strategic benefit, value and market access to their investment companies. They partner with organizations that share their vision and values of improving quality of life during ageing.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• RA Capital Management: Healthcare-focused crossover fund investing across public and private biotech. Comparable as a science-driven, IP-focused investor with deep biotech domain expertise and multi-stage deployment.
• OrbiMed: Healthcare-dedicated investment firm across private and public markets. Comparable as a globally focused, life sciences-specialised investment platform with multi-stage capabilities.
• LongeVC: Venture firm investing in early-stage longevity and biotech companies. Highly comparable to Oshen's Better Ageing thesis as a focused, science-led investor in human longevity and ageing-related therapeutics.
• Apollo Ventures: Longevity-focused venture fund targeting ageing biology and age-related disease. Highly comparable as a small, science-driven, thematic investor focused on the Better Ageing space.
• ARCH Venture Partners: Long-tenured US venture firm investing in early-stage biotech and deep tech companies. Directly comparable as a science-driven, IP-rich, early-to-growth stage life sciences investor with operational involvement.
• Juvenescence: Longevity-focused biotech holding company building and investing in therapies targeting ageing. Comparable to Oshen as an evergreen-style, IP-rich investor focused exclusively on the Better Ageing / longevity thesis.
• Atlas Venture: Early-stage biotech venture firm that builds companies from inception through clinical development. Comparable as a science-led, IP-focused, early-to-mid stage biotech investor with operational involvement.
• Flagship Pioneering: Biotech creation and venture firm that originates and builds breakthrough life sciences companies. Comparable to Oshen as a deep-science, IP-rich, hands-on investor across the biotech product life cycle.
• Versant Ventures: Healthcare-focused venture firm investing across biotech, medtech, and healthcare services. Comparable as a multi-stage, IP-rich investor with deep scientific networks and global deal sourcing.

Broad incumbents

• Khosla Ventures: Large diversified venture firm with material life sciences exposure. Comparable as a science-led investor in IP-rich biotech and medtech, though significantly larger and broader in scope than Oshen's focused Better Ageing mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oshen